The world of biologics

Lupus

Volumn 15, Issue 3, 2006, Pages 122-126

  Symmons, Deborah P M ^a   Silman, A J ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

Anti TNF therapy; Infection; Mortality; Pharmacovigilance; Rheumatoid arthritis

Indexed keywords

ADALIMUMAB; ETANERCEPT; INFLIXIMAB; METHOTREXATE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT;

CANCER; COMORBIDITY; CONFERENCE PAPER; DEMOGRAPHY; HUMAN; INFECTION; LUNG FIBROSIS; MEDICAL RESEARCH; MORTALITY; PRACTICE GUIDELINE; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS;

ANTIBODIES, MONOCLONAL; ARTHRITIS, RHEUMATOID; HUMANS; PULMONARY FIBROSIS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33646008867     PISSN: 09612033     EISSN: None     Source Type: Journal    
DOI: 10.1191/0961203306lu2278rr     Document Type: Conference Paper

References (15)

1. Prevoo ML, van't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995; 38: 44-48.
2. National Institute for Clinical Excellence. Guidance on the use of etanercept and infliximab for rheumatoid arthritis. NICE Technology Appraisal London, NICE 2002; 36.
3. van Gestel AM, Haagsma CJ, van Riel PL. Validation of rheumatoid arthritis improvement criteria that include simplified joint counts. Arthritis Rheum 1998; 41: 1845-1850.
4. Hyrich H, Watson K, Symmons D, Silman A. Predicting response to anti-TNF alpha therapy among patients with rheumatoid arthritis. Rheumatology (Oxford) 2005; 44 (Suppl 1): i24.
5. Duthie JJ, Brown PE, Truelove LH, Baragar FD, Lawrie AJ. Course and prognosis in rheumatoid arthritis. A further report. Ann Rheum Dis 1964; 23: 193-204.
6. Lewis P, Hazleman BL, Hanka R, Roberts S. Cause of death in patients with rheumatoid arthritis with particular reference to azathioprine. Ann Rheum Dis 1980; 39: 457-461.
7. Prior P, Symmons DP, Hawkins CF, Scott DL, Brown R. Cancer morbidity in rheumatoid arthritis. Ann Rheum Dis 1984; 43: 128-131.
8. Chehata JC, Hassell AB, Clarke SA et al. Mortality in rheumatoid arthritis: relationship to single and composite measures of disease activity. Rheumatology (Oxford) 2001; 40: 447-452.
9. Symmons DP, Jones MA, Scott DL, Prior P. Longterm mortality outcome in patients with rheumatoid arthritis: early presenters continue to do well. J Rheumatol 1998; 25: 1072-1077.
10. Symmons DP, Silman AJ. Anti-tumor necrosis factor alpha therapy and the risk of lymphoma in rheumatoid arthritis: no clear answer. Arthritis Rheum 2004; 50: 1703-1706.
11. Baecklund E, Ekbom A, Sparen P, Feltelius N, Klareskog L. Disease activity and risk of lymphoma in patients with rheumatoid arthritis: nested case-control study. Brit Med J 1998; 317: 180-181.
12. Doran MF, Crowson CS, Pond GR, O'Fallon WM, Gabriel SE. Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study. Arthritis Rheum 2002; 46: 2287-2293.
13. Dixon W, Hyrich K, Watson K, Silman A, Symmons D. Serious infection rates in patients receiving biologic therapy in the United Kingdom: results from the BSR Biologies Register. Rheumatology (Oxford) 2005; 44 (Suppl 1): i11.
14. Ostor AJ, Crisp AJ, Somerville MF, Scott DG. Fatal exacerbation of rheumatoid arthritis associated fibrosing alveolitis in patients given infliximab. Brit Med J 2004; 329: 1266.
15. Watson K, Hyrich K, Silman A, Symmons D. Mortality among RA patients receiving anti-TNF alpha therapy in the United Kingdom: results from the BSR Bologics Register. Rheumatolog 2005; 44 (Suppl 1): i23.